Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Liver cancer, adult primary
Stage/Subtype:  stage D adult primary liver cancer (BCLC)
Country:  U.S.A.
Trial Type:  Treatment
Results 1-21 of 21 for your search:
Start Over
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-459, NCI-2015-01952, NCT02576509
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Ipilimumab and Hypofractionated Stereotactic Body Radiation Therapy in Treating Patients with Advanced Solid Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0882, NCI-2015-00042, NCT02239900
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBIHCC-103, NCI-2014-02447, BBI608-503-103HCC, NCT02279719
Trial of TRC105 and Sorafenib in Patients With HCC
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 105HCC101, NCI-2016-00131, NCT02560779
A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA223-001, NCI-2014-00201, NCT01714739
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 54F28-004, NCI-2014-00645, NCT02069145
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARQ197-A-U160, NCI-2014-01712, NCT02150733
Erismodegib in Treating Patients with Advanced or Metastatic Liver Cancer That Cannot Be Removed by Surgery or Child-Pugh A Cirrhosis
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLDE225XUS12T, NCI-2014-01762, 131053, HRPP #131053, NCT02151864
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SM04755-ONC-01, NCI-2014-02297, NCT02191761
Ganetespib and Ziv-Aflibercept in Treating Patients with Refractory or Metastatic Gastrointestinal Cancer, Non-small Cell Lung Cancer, Urothelial Cancer, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14-C-0150, NCI-2014-00626, 09-25-0099, 141525, P141525, 9605, NCT02192541
Trametinib and Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17932, NCI-2014-02614, 14.10.0021, MCC 17932, NCT02292173
A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B0601002, NCI-2015-00761, 2014-004107-75, NCT02315066
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC GI1536, NCI-2014-02475, 9824, NCT02319018
Study of E7046 in Subjects With Selected Advanced Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E7046-G000-101, NCI-2015-01544, NCT02540291
A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BLU-554-1101, NCI-2015-01683, 2015-001662-26, NCT02508467
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 229812, NCI-2013-01198, NCT01896778
Radiolabeled Glass Beads in Treating Patients with Liver Cancer That Cannot be Surgically Removed
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-10036, NCI-2012-00877, 2010C0053, NCT02072356
Sorafenib Tosylate in Treating Patients with Liver Cancer That Cannot Be Removed by Surgery
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: I 238913, NCI-2014-00180, NCT02072486
Gemcitabine Hydrochloride, Cisplatin, and Yttrium Y 90-TARE in Treating Patients with Liver Cancer That Cannot Be Removed by Surgery
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 102254, NCI-2015-01276, MUSC 102254, NCT02512692
Start Over